Exact Sciences Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 2/17/2026)
| Balance Sheet | Total Assets | 5,860,630,000.00 | ROE | – |
| Balance Sheet | Total Equity | 2,401,050,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -134,656,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 356,782,016.00 | – | – |
| Cashflow | Operating Cash Flow | 491,438,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -1.10 | Div. Yield | – |
| Income | Net Income | -207,949,000.00 | P/E | – |
| Income | Shares Outstanding | 188,688,000.00 | P/B | – |
| Income | Total Revenue | 3,246,990,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company´s Cologuard test is a non-invasive, stool-based DNA (sDNA) screening test designed to detect deoxyribonucleic acid (DNA) markers, which in published studies have been shown to be associated with colorectal cancer. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test (FIT). The Company´s Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The target sensitivity rate of its Cologuard test for cancer is equal to or greater than 85% at a specificity of 90%.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.exactsciences.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more